Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol

VHJ van der Velden, A van der Sluijs-Geling, BES Gibson, JGT Marvelde, PG Hoogeveen, WCJ Hop, Keith Wheatley, MB Bierings, GJ Schuurhuis, SSN de Graaf, ER van Wering, JJM van Dongen